Gujarat to Play Key Role as India Eyes $450B Pharma Sector by 2047
Ahmedabad, October 23: Experts from the pharmaceutical sector on Friday underlined that taking India's pharma industry to new global heights will require strong alignment between industry, the government, regulators and academic bodies. Their remarks focused on Gujarat's growing importance as a pharma hub.
At the CII Pharma Summit 2026, Dr. Viranchi Shah, President of the Indian Drug Manufacturers' Association (IDMA), described India as the “Pharmacy of the World” and called Gujarat the country's pharma capital. According to him, Gujarat accounts for around 30 percent of India's total pharmaceutical manufacturing.
He said the leadership of Prime Minister Narendra Modi has set a broader goal for the sector. The aim is to remain the largest volume producer while also building leadership in value-added products and innovation. Government policies and industry efforts are already working toward this objective.
Dr. Shah projected that if current momentum holds, the Indian pharma industry could grow to about $450 billion by 2047, in the Amrit Kaal period. The summit, he said, is meant to bring stakeholders together to agree on the actions required to reach that milestone.
Green chemistry and environmental compliance also feature prominently in the sector's strategy, Dr. Shah said. New bulk drug parks are adopting global standards for effluent treatment and pollution control.
“Pharma does more than save lives. The industry also wants to make sure it does not contribute to the world's pollution problem,” he remarked. He added that the sector is embracing sustainable and environment-friendly development.
Dr. Shah further pointed to pharmaceuticals as a major area of India-US strategic cooperation. He cited recent bilateral discussions and said both nations are placing the sector high on their shared economic and strategic agenda.
He also said that a significant share of the American drug supply chain may move to India in the coming years. Such a shift, he suggested, would strengthen India's industry while helping the US secure affordable medicines and healthcare services.